Loading stock data…
AXSM
$216.47-0.91 (-0.42%)
Market ClosedLast close May 11
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Axsome Therapeutics, Inc. in the Healthcare sector is trading at $216.47. The stock is currently near its 52-week high of $234.29, remaining 43.4% above its 200-day moving average. Technical signals show overbought RSI of 76 and bullish MACD crossover, explaining why AXSM maintains its current momentum and trend strength. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Overbought levels (RSI 76) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$216.47
Potential Upside
5%
Whystock Fair Value$227.29
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Mean target$270.28+24.9%
Range$200.00 – $328.81
Fundamentals
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextrometho...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-279.63%
Volume
Today's trading volume
632,683
Recent News
Why These Four Biotech Stocks Prove That Follow-On Entries Still Pop Up In Stock Market Leaders
Truth be told, a survey of leading biotech stocks currently in the IBD 50 actually accentuates the importance of using both daily and weekly charts in the same manner as, say, the mega-cap leaders such as Sandisk, Micron Technology, and Western Digital in the data storage segment. The concept also applies to other tech leaders such as Marvell Technology in application-specific integrated circuits, and Ciena, a fiber-optic data networking company. Marvell carries a $140 billion market cap, and Ciena is valued at $76 billion.
3 Stocks Poised to Disrupt the Healthcare Market by 2030
The old healthcare model is breaking down.
Assessing Axsome Therapeutics (AXSM) Valuation After Strong Recent Share Price Momentum
Axsome Therapeutics: Stock Performance Snapshot Axsome Therapeutics (AXSM) stock has attracted investor attention after a strong run, with the share price at US$222.63 and total return figures over the past year and past 3 months drawing closer scrutiny. See our latest analysis for Axsome Therapeutics. The recent 7 day share price return of 21.03% and 30 day share price return of 31.16%, alongside a 1 year total shareholder return of 100.82%, point to momentum that has built over time rather...
How The Axsome Therapeutics (AXSM) Story Is Shifting After Auvelity And AXS 05 Developments
The Street’s updated fair value estimate for Axsome Therapeutics has shifted from US$223.99 to US$266.94, signaling a different view on potential upside built into current models. That reset is tied to fresh analyst work on Auvelity, the AXS-05 PDUFA decision for Alzheimer’s disease agitation, and how quickly the broader pipeline and indications might translate into cash generation. Below, you will see what is driving these shifting price targets and how to track the story as new data and...
Is Axsome Therapeutics (AXSM) Starting To Look Fully Priced After Its 1-Year Share Price Surge?
Wondering whether Axsome Therapeutics at US$222.63 is starting to look expensive or if the price is still catching up to its story? This article breaks down what that current level might mean for value focused investors. The stock has moved sharply in recent periods, with returns of 21.0% over 7 days, 31.2% over 30 days, 24.6% year to date, 100.8% over 1 year, 177.5% over 3 years and 290.5% over 5 years. These moves are set against a backdrop of ongoing interest in pharmaceuticals and...